相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原:
The antiserum was produced against a chemically synthesized phosphopeptide derived from a region of human PKCbI and II that contains threonine 500.
- 亚型:
IgG
- 形态:
Liquid
- 保存条件:
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
- 克隆性:
Polyclonal
- 标记物:
Unconjugated
- 适应物种:
Human, Rat
- 保质期:
12 months from the shipping date of the product.
- 抗原来源:
Human
- 目录编号:
GTX25817
- 级别:
Primary Antibodies
- 库存:
Available
- 供应商:
GeneTex
- 宿主:
Rabbit
- 应用范围:
WB
- 浓度:
Batch dependent (Please refer to the vial label for the specific concentration.)
- 靶点:
This antibody cross-reacts with PKC alpha [pT497] (88% homologous) and partially cross-reacts with PKC gamma [pT514] (63% homologous) and epsilon [pT566] (75% homologous), as determined by peptide competition experiments.
- 抗体英文名:
PKC beta (phospho Thr500) antibody
- 抗体名:
PKC beta (phospho Thr500) 抗体
- 规格:
50 μl
WB analysis of K562 cells stimulated with PMA using GTX25817 PKC beta (phospho Thr500) antibody. The membrane treated with phosphatase (Lane 5) eliminates the signal verifying that the antibody is phospho-specific.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Guorong Lin et al., PLoS One 2014 (PMID:24466133)
9921 Phospho-PKC Antibody Sampler Kit 9375 Phospho-PKCalpha/beta II (Thr638/641) Antibody W IP 9374 Phospho-PKCdelta (Thr505) Antibody W IHC 9376 Phospho-PKCdelta/theta (Ser643/676) Antibody W IHC 9377 Phospho-PKCtheta (Thr538
Anticardiolipin Antibody and Anti-beta 2 Glycoprotein I Antibody Assays
) antibodies and anti-beta 2 glycoprotein I (β2-GPI) antibodies. Other autoantibodies, such as those directed against anionic phospholipids, can also be assayed; however they are not of clinical significance. Participation in a quality assurance
真爱满行囊 我最近在体外细胞做的关于gsk3-beta功能问题,发现药物处理以后,gsk-3-beta的总表达量下调,如果是这样的话 1、我是否能够得出gsk-3-beta的活性下调的结论? 2、是否还有必要做非活性形式的表达量?我的理解是,基础状态下,gsk-3beta维持的是低活性状态,如果总量都下调了,那应该能够得出活性降低的结论了吧? 3、另外,在这种情况下我是否有必要去做gsk-3-beta的216位点的活性形式的表达
技术资料暂无技术资料 索取技术资料





![ZNF323 antibody [N1C3]](https://img1.dxycdn.com/2023/0516/895/8887749495766728561-14.jpg!wh200)


![DCTN1 antibody [C3], C-term](https://img1.dxycdn.com/2023/0711/255/2344116916935858761-14.jpg!wh200)
